CD274 and cancer: In the present VolATIL clinical trial, we will evaluate the clinical interest and immunological efficacy of a treatment combining the UCPVax with anti–PD-L1 therapy (atezolizumab) in patients with HPV+ cancers (anal canal, cervix and vulvar, and oropharyngeal cancers) by evaluation of the objective response rate (ORR) at 4 months according to iRECIST criteria.